Incidence Density of Invasive Fungal Infections during Primary Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Patients in a Tertiary Cancer Center, 2009 to 2011
暂无分享,去创建一个
[1] John Moore,et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. , 2013, The Lancet. Infectious diseases.
[2] H. Einsele,et al. Combined real‐time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies , 2013, British journal of haematology.
[3] G. Gastl,et al. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. , 2012, The Journal of antimicrobial chemotherapy.
[4] R. Foà,et al. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience , 2012, Haematologica.
[5] Tim Spelman,et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period , 2012, Haematologica.
[6] Russell E. Lewis,et al. Importance of Pharmacokinetic Considerations for Selecting Therapy in the Treatment of Invasive Fungal Infections , 2012, American journal of therapeutics.
[7] D. Kontoyiannis,et al. Resistance to echinocandins comes at a cost , 2012, Virulence.
[8] R. Haupt,et al. Empirical versus pre-emptive antifungal therapy for persistent febrile neutropenia , 2012, Haematologica.
[9] E. Estey,et al. Continuing medical education activity in American Journal of Hematology , 2011 .
[10] F. Grenouillet,et al. Candida spp. with Acquired Echinocandin Resistance, France, 2004–2010 , 2012, Emerging infectious diseases.
[11] D. Kontoyiannis. Invasive mycoses: strategies for effective management. , 2012, The American journal of medicine.
[12] M. Roberts,et al. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. , 2012, International journal of antimicrobial agents.
[13] A. Tortorano,et al. Cross-Reactivity of Fusarium spp. in the Aspergillus Galactomannan Enzyme-Linked Immunosorbent Assay , 2011, Journal of Clinical Microbiology.
[14] F. Dromer,et al. Prior Caspofungin Exposure in Patients with Hematological Malignancies Is a Risk Factor for Subsequent Fungemia Due to Decreased Susceptibility in Candida spp.: a Case-Control Study in Paris, France , 2011, Antimicrobial Agents and Chemotherapy.
[15] R. Lewis. Current concepts in antifungal pharmacology. , 2011, Mayo Clinic proceedings.
[16] S. Lockhart,et al. Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the cyp51A Gene , 2011, Antimicrobial Agents and Chemotherapy.
[17] J. Donnelly,et al. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? , 2011, British journal of haematology.
[18] Steven D. Brown,et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[19] G. Wassmer,et al. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients , 2011, Mycoses.
[20] A. Thiébaut,et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.
[21] Russell E. Lewis,et al. Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia Species , 2011, Clinical Microbiology Reviews.
[22] L. Pagano,et al. Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. , 2011, Medical mycology.
[23] D. Kontoyiannis. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success , 2011, Bone Marrow Transplantation.
[24] E. Holler,et al. Clinical experience with posaconazole prophylaxis – a retrospective analysis in a haematological unit , 2011, Mycoses.
[25] F. Dromer,et al. Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients , 2010, Antimicrobial Agents and Chemotherapy.
[26] M. Hallek,et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. , 2010, The Journal of antimicrobial chemotherapy.
[27] D. Kontoyiannis,et al. Fungal infections in leukemia patients: how do we prevent and treat them? , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] V. Preedy,et al. European Organization for Research and Treatment of Cancer , 2010 .
[29] Russell E. Lewis,et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001‐2007) , 2009, Cancer.
[30] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[31] H. Einsele,et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology , 2009, Haematologica.
[32] H. Kantarjian,et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome , 2009, Supportive Care in Cancer.
[33] L. Pagano,et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? , 2008, European journal of haematology.
[34] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] J. Szer,et al. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy , 2008, Internal medicine journal.
[36] J. Wingard,et al. Changes in causes of death over time after treatment for invasive aspergillosis , 2008, Cancer.
[37] T. Walsh,et al. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. , 2007, Diagnostic microbiology and infectious disease.
[38] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[39] J. Fine,et al. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] E. Estey,et al. Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies , 2006, Antimicrobial Agents and Chemotherapy.
[41] D. Kontoyiannis,et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.
[42] L. Pagano,et al. Design and Methods , 2022 .
[43] W. Leisenring,et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] Russell E. Lewis,et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.
[45] D. Denning. Echinocandin antifungal drugs , 2003, The Lancet.